STUDY OBJECTIVE The use of benzodiazepines and the development of dementia is controversial, with studies indicating that benzodiazepines could be either a protective factor or a risk factor for dementia, or no association may exist between the two. Our objective was to identify whether such an association exists. DESIGN Systematic review and meta-analysis of 12 prospective and retrospective cohort studies and case-control studies. PARTICIPANTS A total of 981,133 (in the systematic review) and 980,860 (in the meta-analysis) adults or elderly individuals.
dementia, with studies indicating that the use of BZDs could be either a protective factor 6 or a risk factor, [7] [8] [9] [10] [11] [12] [13] or that no association exists between the two at all. 14 Previous systematic reviews and meta-analyses have been published, identifying the use of BZDs as a risk factor for dementia. 15, 16 However, since their publication, new primary studies were published, [11] [12] [13] and their results may modify the previously identified effects of BZDs because in recent years a potential bias was suggested in these analyses due to the lack of adjustment of confounding factors. Prodromal symptoms, such as poor sleep quality and episodes of anxiety, may manifest 10 years before the clinical diagnosis of dementia, which could be the reason for the first prescription of BZD, generating a reverse causal association with regard to the hypothesis of the association between the use of BZDs and subsequent dementia. 17, 18 Considering the differing conclusions in the literature, our objective was to conduct a metaanalysis of observational studies to provide evidence-based hierarchies of the association between the use of BZDs and the development of dementia.
Methods

Study Design
In this systematic review and meta-analysis, we followed the recommendations for research design and reporting to guarantee the quality, transparency, and consistency of the study. [19] [20] [21] Details of this systematic review were recorded in the PROSPERO database (CRD42017056122). 22 
Search Strategy and Selection Criteria
The evaluated population included adults and elderly individuals without sex restrictions or health problems, and the effects of ever users of BZDs were compared with nonusers of BZDs. Cohort and case-control studies that assessed the association of developing dementia with the use of BZDs were eligible for inclusion in this study. Studies that did not accurately report treatment or outcomes and those that included patients with dementia at the start of the study were excluded.
A search of the PubMed, LILACS, and Cochrane Central Register of Controlled Trials databases (updated September 2017), without any time limit or language restrictions, was conducted. Manual searches of the reference lists of the included publications and reviews were also performed. Table A1 lists the complete search  strategies. Two researchers independently screened the titles and abstracts of the retrieved studies to identify irrelevant records (R.C.L. and B.P.M.M.). In the second stage, full-text articles were also independently evaluated by two researchers, according to the defined inclusion and exclusion criteria. Discrepancies were conciliated in consensus meetings using a third researcher as a referee (P.C.M.).
Data Analysis
The following data were independently extracted by two researchers using Microsoft Excel software (Microsoft Corp., Redmond, WA): baseline characteristics of the studies (authors' names, year of publication, country, sample size, patients' sex and age, alternatives assessed, follow-up period duration, exposure assessment, and diagnostic criteria), methodological aspects (e.g., study design), and clinical outcome results (dementia).
The critical evaluation of the bias risk of the included studies was conducted by two independent reviewers using the Newcastle-Ottawa Scale (NOS). 23 In the absence of consensus, points of disagreement were resolved by the opinion of a third researcher.
Statistical analyses were performed using R v.3.4.1/R studio 1.0.153 24 statistical software packages READR, 25 META, 26 and METAFOR.
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A meta-analysis of the main analyses was conducted by using a random effects model by Hartung-Knapp and the s 2 estimator from SidikJonkman, due to the high expected heterogeneity, and the Higgins inconsistency test (I 2 ) was used for the evaluation of heterogeneity. The results were summarized according to odds ratio (OR), 95% confidence interval (CI), and 95% prediction interval (PI). In cases of meta-analyses containing 10 or more studies, the probability of publication bias was evaluated with a statistical test based on the Harbor test and visual analysis of the presence of asymmetry in the funnel plot. The main analysis considered adjusted estimates for confounding variables, when available. Due to the heterogeneity of the variables considered or even to the presence of more than one adjusted analysis for the same study, it was decided the adjusted analysis that presented the smallest measure of effect would be used.
Sensitivity analyses were performed to validate the conclusions using alternative analyses compared with the main analysis: use of the MantelHaenszel method with the DerSimonian-Laird estimator for s 2 instead of Hartung-Knapp and Sidik-Jonkman; use of only adjusted studies instead of unadjusted and adjusted studies; use of only studies with lag times or run-in periods to minimize protopathic bias instead of studies with no lag time; and use of relative risk (RR) as measure of effect instead of OR. In addition, exclusion of studies one at a time was also performed. The subgroup analyses considered the following: type of BZD, action of BZD, type of dementia, study design, and diagnostic classification.
The quality of the evidence was assessed with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group certainty ratings 28 and was classified as high, moderate, low, or very low confidence.
Results
Our systematic review identified 583 records after removal of any duplicates and 4 by manual search; of these, 559 were considered irrelevant during the screening, and 17 were excluded during the full-text appraisal (Figure 1) . A list of the excluded studies categorized by reason for exclusion is provided in Table A2 . The remaining 11 records represented 12 different studies that were included in the systematic review (the same article 10 reported a case-control study and cohort study). The included articles were published between 2011 and 2017. Seven studies were case-control studies, 4 were prospective cohort studies, and 1 was a retrospective cohort study. The studies had follow-up periods ranging from 72-264 months. The studies included in the systematic review totaled 981,133 participants and totaled 980,860 participants in the main meta-analysis (Table 1) .
Methodological quality, as assessed by the NOS, is presented in Table 2 . Most of the studies were rated as high quality, defined as attaining six or more stars. Most studies were adjusted for age, sex, comorbidities, and socioeconomic factors, as well as for lifestyle factors. However, one group 11 reported adjusted analyses only within each cumulative dose subgroup.
All studies were entered into the main metaanalysis except for a case-control study 29 and a cohort study 10 because the case-control study compared high-dose with low-dose BZD instead of BZD users with nonusers, 29 and the cohort study had participants who overlapped with those in the case-control study in the same article. 10 However, because one report 29 described dementia development between short-acting versus long-acting benzodiazepines, it was considered in the subgroup analysis.
Of the 11 studies included in the main meta-analysis, 8 identified that the use of BZD is a risk factor for the development of dementia, 7, 8, [10] [11] [12] [30] [31] [32] 2 showed no association between BZD and dementia, 13, 14 and 1 showed that use of BZD was a protective factor in the development of dementia. 33 Thus the main meta-analysis found that BZD users are 1.38 times more likely to develop dementia than nonusers (OR 1.38, 95% CI 1.07-1.77) and that BZD users have a 28% higher risk of developing dementia (RR 1.28, 95% CI 1.06-1.55). However, the analysis showed high heterogeneity and PIs, suggesting that future studies may be able to identify different magnitude effects ( Figure 2) .
Most of the subgroup analyses did not confirm the association between the use of BZDs and the development of dementia, except for those using the International Classification of Diseases, Ninth Revision and the International Classification of Diseases, Tenth Revision (Table 3) . It is important to note that the direct comparison between users of short-acting BZDs and users of long-acting BZDs indicated a lack of a significant difference in the development of dementia, with wide CIs and PIs (OR 1.13, 95% CI 0.92-1.40, 95% PI 0.67-1.93; I 2 43%). Several studies reported evidence for the association between dementia and old users (compared with nonusers) of BZDs 8, 10 and moderate doses of BZDs. 11 However, due to the inconsistent reports of the outcome results, it was not possible to perform subgroup metaanalyses to synthesize the evidence. Table 4 presents sensitivity analyses with alternative estimation measures (ORs or RRs) and alternative statistical models (HartungKnapp or DerSimonian-Laird) and scenarios, including only studies that controlled for protopathic bias or adjusted estimates. Most of the sensitivity analyses corroborated the findings of the main analysis, except when only studies that controlled for protopathic bias and adjusted analyses were considered ( Table 4 ). The publication bias analysis identified no publication bias either according to the visual analysis of the funnel plot or the statistical test (Figure 3) .
The association between the use of BZDs and the development of dementia was supported by evidence of very low quality (GRADE rating system). Despite presenting high methodological quality, direct evidence, and precision, the studies in this meta-analysis were characterized by high heterogeneity.
Discussion
In our study, we identified that the use of BZDs was associated with the development of dementia; however, future studies should identify different estimates, with consideration of confidence in both very low quality evidence and broad and nonsignificant predictive intervals. A similar relationship was identified in three metaanalyses. 15, 16, 34 However, we noticed differences in the selection of the included studies, as well as in how the analyses were conducted, that may change the interpretation of the findings. The three meta-analyses included two studies derived from the same cohort, Personnes Ag ees Quid-PAQUID, 9, 10 thereby overestimating the risk for dementia by duplicating participants; the three included one study comparing long-term BZD users with recent BZD users, 35 and one report 34 included one study comparing users of high-dose with low-dose BZDs, which is in contrast to the meta-analyses comparing BZD nonusers with BZD ever users. Thus, these previous analyses suggest that use of BZDs causes dementia compared with nonuse of BZDs, former use of BZDs, or low cumulative BZD doses, but also when compared with only nonuse of BZDs, as suggested by the present analysis.
To clarify the hypothesis of reverse causality, the primary studies used intense screening at baseline to evaluate for cognitive impairment Figure 1 . Flowchart of the study selection process (Preferred Reporting Items for Systematic Reviews and Meta-analysis).
that was already present in participants (possibly to characterize dementia) before the beginning of the study. In addition, the studies introduced a latency period (lag time) before the follow-up period, during which there could be no diagnosis of dementia made or use of BZDs. Subgroup analyses that considered studies with lag times to minimize protopathic bias highlighted the importance of primary studies that considered this latency period because the analyses without lag times showed a lack of association of BZDs with dementia, possibly because some of the patients who developed dementia during the study already had dementia before the use of BZDs.
The main difference between the previously cited study 34 and the present analysis becomes evident when comparing the findings for the adjusted analyses when controlling for protopathic bias. Although the group found an association of BZD use with dementia even when only studies that included a lag time to minimize protopathic bias were considered, in the present analysis, no statistically significant association was found when we analyzed only studies that controlled for protopathic bias. The Asterisks indicate that the quality item is present. A study can be awarded a maximum of one asterisk for each numbered item within the selection and exposure or outcome categories. A maximum of two asterisks can be given for comparability (i.e., study controls for the most important factor and any additional factor). The total number of asterisks represents the final score. 1A = representativeness of the exposed cohort; 2A = selection of the nonexposed cohort; 3A = ascertainment of exposure; 4A = outcome was not present at start of study; 5A = comparability of cohorts on the basis of the analysis; 6A = assessment of outcome; 7A = follow-up was long enough for outcome to occur; 8A = adequacy of follow-up of cohorts; 1B = case definition was adequate, 2B = representativeness of the cases; 3B = selection of controls, 4B = definition of controls; 5B = comparability of cases and controls on the basis of analysis; 6B = ascertainment of exposure; 7B = same method of ascertainment for cases and controls; 8B = nonresponse rate. difference in the CIs found is probably due to the choice of statistical method used because in the present analysis we used the random effects model by Hartung-Knapp due to high heterogeneity. The other study used DerSimonianLaird, which is employed in meta-analyses of studies of high heterogeneity or for a small number of studies, although more frequently, it can overestimate effect measures, leading to type I errors (i.e., when the null hypothesis is contradicted erroneously). 36 The adjusted and unadjusted estimates highlighted that the unadjusted analyses overestimated the risk for developing dementia. Despite the knowledge that the prevalence of dementia and the use of BZDs are higher in female subjects, 37 and although age is a risk factor for developing dementia, a study 8 conducted in a cohort with a mean age of 62 years demonstrated the highest risk for developing dementia, even in its adjusted analysis. Their findings suggested that, although adjustment for confounding variables reduces the measure of an associative effect, studies that are not influenced by female sex or older people demonstrate a less masked association of the use of BZDs with dementia.
The subgroup analyses of the present review were not robust enough to identify differences in the association depending on the type of dementia and the actions of BZDs. Despite the limited evidence available for these assessments, the meta-analysis that compared development of dementia in short-acting BZD users with never users, and long-acting BZD users with never users, corroborated the cited findings. 15, 16, 34 Although development of dementia was associated with long-acting BZD use, the same was not shown for short-acting BZD use. However, in light of the overlap of CIs for the two comparisons and the absence of an association with the development of dementia when comparing users of short-acting with long-acting BZDs, we cannot suggest that short-acting BZDs are safe relative to the development of dementia, although the trend favors the use of short-acting BZDs. The premise that long-acting BZDs are associated with more adverse events than short-acting BZDs is represented in several lists of potentially inappropriate treatments for older individuals, 38, 39 in which short-acting BZD are recommended as safer because of their reduced potential to cause drowsiness and falls. 40 It is interesting to note that midazolam, a short-acting BZD, is not cited on any list; it is the only BZD marketed that is not considered potentially inappropriate treatment for the elderly.
However, the same premise cannot be extrapolated to the association between BZD use and dementia, at least with the evidence available today and that is included in this meta-analysis. In a study that used a data mining technique, 41 a strong association between BZD use and antidementia drugs was identified when considering U.S. and Canadian pharmacovigilance data, and a greater association when considering the use of long-duration BZDs and long-acting BZDs, although shortand medium-acting BZDs were also found to have an association with antidementia drugs.
Regarding the quality of the evidence, a systematic review 42 without meta-analysis found that studies with average or good confidence reported a strong association between the use of BZDs and dementia (OR ranging from 1.24-2.30) that corroborated our findings. However, in the present analysis, the quality of the evidence used the GRADE tool that includes criteria other than methodological quality. In this sense, it is important to emphasize that heterogeneity was responsible for the very low confidence, although it is common for meta-analyses of observational studies to present high heterogeneity. 43 In addition, attempts to explain the high heterogeneity were not successful, considering that in both subgroup and sensitivity analyses, the lowest heterogeneity found was 65%, which is still significant. It is worth noting that although high statistical heterogeneity was identified, it is possible that it did not contribute to a reduction in the confidence of the evidence regarding the direction of the effect, but only in the magnitude, because 8 of the 12 studies found that the use of BZD was associated with the development of dementia. In this sense, we recommend the cautious interpretation of very low confidence, not ruling out the need for new prospective long-term studies (face to face) with the following: statistical power for identification of a high-magnitude effect, adequate adjustment for confounding variables, strategies to minimize reverse causality (e.g., latency periods or lag times, minimizing the inclusion of patients with dementia at baseline), reporting of subgroups aimed at greater homogeneity of the findings, and defined daily dose analyses for dose-response gradient identification.
Regarding the limitations of this review, we highlight the exclusion of records from the gray literature, which was justifiable due to the low probability of obtaining reliable and complete data for inclusion in the meta-analyses from these sources.
Conclusion
Our results suggest an association between BZD use and the development of dementia. However, the current evidence lacks the power to infer differences between the effects of Alzheimer's disease and vascular dementias, longacting and short-acting BZDs, and various exposure loads (duration and dose). Therefore, future studies may identify different estimates considering both the confidence in very low quality evidence and the broad and nonsignificant PIs. 
